Skip to content
Find a Provider
Brea C. Lipe, M.D.

Brea C. Lipe, M.D.

Hematology & Oncology , Cancer

4.9 out of 5 stars
524 Ratings
56 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5823
Fax (585) 273-1051

About Me

I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in th...
I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in the last 10 years. The rapid pace of change, intrinsic disease complexity, and the ability to impact patient lives still leaves me amazed and humbled every day.

I believe that it's important to know my patients as individuals to understand the situational circumstance and personality that drives their treatment goals. Multiple myeloma is a lifelong journey and a strong partnership with my patients is essential to achieving the best quality of care. I have a strong interest in clinical research and like to offer my patients a variety of clinical trial options and treatments based on the most recent data. I have a dedicated support team, so that we can offer patients a team with real myeloma-specific expertise.

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Outside of work, I love to grow things -- flowers, vegetables, orchids, animals, children. I have gotten some of my best gardening tips from my patients.

Conditions I treat:

- Multiple myeloma
- Other plasma cell disorders

Certified Specialties

Hematology - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, Dartmouth-Hitchcock Medical Center. 2008 - 2011

Residency, Internal Medicine, Dartmouth-Hitchcock Medical Center. 2006 - 2008

Internship, Internal Medicine, Dartmouth-Hitchcock Medical Center. 2005 - 2006

Education

MD | Albany Medical College. 2005

Awards

Leadership Academy. 2017

Department of Internal Medicine OSARM Faculty Incubator Scholar. 2011

Clinical Research Training Institute Clinical Scholar for ASH. 2011

Award for Excellence in Teaching. 2009

Award for Excellence in Teaching. 2007

Frank C. Knievel Scholarship Award. 2001 - 2005

First Generation Diversity Scholarship. 1996 - 2001

Research

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is ...
In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Clinical Trials

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

Lead Researcher: Brea C Lipe

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail ...

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

Publications

Journal Articles

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies.

Keren DF, Bocsi G, Billman BL, Etzell J, Faix JD, Kumar S, Lipe B, McCudden C, Montgomery R, Murray DL, Rai AJ, Redondo TC, Souter L, Ventura CB, Ansari MQ

Archives of pathology & laboratory medicine.. 2022 May 1146 (5):575-590. Epub 1900 01 01.

Bisphosphonates for delivering drugs to bone.

Sun S, Tao J, Sedghizadeh PP, Cherian P, Junka AF, Sodagar E, Xing L, Boeckman RK, Srinivasan V, Yao Z, Boyce BF, Lipe B, Neighbors JD, Russell G, McKenna CE, Ebetino FH

British journal of pharmacology.. 2021 May 178 (9):2008-2025. Epub 04/10/2021.

Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma - Moving Toward a Personalized Approach.

Grant SJ, Lipe B

Clinical lymphoma, myeloma & leukemia.. 2020 September 20 Suppl 1 (Suppl 1):S76-S80. Epub 1900 01 01.

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.

Nathwani N, Kurtin SE, Lipe B, Mohile SG, Catamero DD, Wujcik D, Birchard K, Davis A, Dudley W, Stricker CT, Wildes TM

JCO oncology practice.. 2020 January 16 (1):e92-e99. Epub 11/25/2019.

Multiple Myeloma Insights: Older Adults With Multiple Myeloma: Q&A on Care Management

Lipe, B.

Medpage Today. 2020; .

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

Gasparetto, C; Lentzsch, S; Schiller, G; Callander, N; Tuchman, S; Chen, C; White, D; Kotb, R; Sutherland, H; Sebag, M; Baljevic, M; Bensinger, W; LeBlanc, R; Venner, C; Bahlis, N; Rossi, A; Biran, N; Sheehan, H; Saint-Martin, J; Van Domelen, D; Kai, K; Shah, J; Shacham, S; Kauffman, M; Lipe, B.

eJHaem. 2020; .

A review of thrombotic microangiopathies in multiple myeloma.

Lipe B, Passero FC, Gleber C, Portuguese AJ

Leukemia research.. 2019 October 85 :106195. Epub 07/29/2019.

Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation.

Lipe B, Divine C, Abhyankar S, Singh AK, Ganguly S, Lin TL, Baran A, Cantilena AR, Bhatti S, Shune L, Abdelhakim H, McGuirk J, Allin D, Aljitawi OS

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2019 September 25 (9):1713-1719. Epub 06/03/2019.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S

The Lancet. Oncology.. 2019 June 20 (6):e302-e312. Epub 1900 01 01.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 May 1037 (14):1228-1263. Epub 04/01/2019.

Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Li D, Chiu G, Lipe B, Hopkins RA, Lillis J, Ashton JM, Paul S, Aljitawi OS

Blood advances.. 2019 April 93 (7):1011-1026. Epub 1900 01 01.

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma.

Hsu CM, Bennett JM, Lipe B

Clinical lymphoma, myeloma & leukemia.. 2019 January 19 (1):e29-e32. Epub 09/05/2018.

Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.

Baker HA, Brown AR, Mahnken JD, Shireman TI, Webb CE, Lipe BC

Cancer medicine. 2019 January 8 (1):455-462. Epub 12/25/2018.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul B, Lipe B, Ocio EM, Usmani SZ

American Society of Clinical Oncology educational book. 2019 January 39 :e176-e186. Epub 05/17/2019.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul, B; Lipe, B; Ocio, EM; Usmani, SZ.

Am Soc Clin Oncol Educ Book. 2019; 39: e176-e186.

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous deletion.

Portuguese AJ, Lipe B

Blood advances.. 2018 December 112 (23):3443-3446. Epub 1900 01 01.

A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics.

Li D, Lin TL, Lipe B, Hopkins RA, Shinogle H, Aljitawi OS

Leukemia research.. 2018 September 72 :105-112. Epub 08/16/2018.

Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS).

Lipe B, Kambhampati S, Veldhuizen PV, Yacoub A, Aljitawi O, Mikhael J

Blood cancer journal.. 2017 December 147 (12):646. Epub 12/14/2017.

Combined deficiency of factor V and factor VIII: management during cardiothoracic surgery.

Howard C, Lipe B

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.. 2017 April 28 (3):267-268. Epub 1900 01 01.

Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation.

Aljitawi OS, Paul S, Ganguly A, Lin TL, Ganguly S, Vielhauer G, Capitano ML, Cantilena A, Lipe B, Mahnken JD, Wise A, Berry A, Singh AK, Shune L, Lominska C, Abhyankar S, Allin D, Laughlin M, McGuirk JP, Broxmeyer HE

Blood.. 2016 December 22128 (25):3000-3010. Epub 10/19/2016.

The role of maintenance therapy in multiple myeloma.

Lipe B, Vukas R, Mikhael J

Blood cancer journal.. 2016 October 216 (10):e485. Epub 10/21/2016.

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A

British journal of haematology.. 2016 September 174 (5):748-59. Epub 05/16/2016.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P,

The New England journal of medicine.. 2016 August 25375 (8):754-66. Epub 1900 01 01.

Monoclonal Gammopathy of Undetermined Significance (MGUS).

Lipe, B; Drurie, B.

Pocket Guide for American Society of Hematology. 2016; .

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.

Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ

Blood cancer journal.. 2015 August 75 (8):e334. Epub 08/07/2015.

IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome.

Howard CR, Lin TL, Cunningham MT, Lipe BC

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.. 2014 September 25 (6):631-3. Epub 1900 01 01.

Toward personalized medicine in acute myelogenous leukemia.

Lin, TL; Lipe, BC.

Personalized Medicine. 2013; 10(6): 427-430.

Bone marrow transplant for multiple myeloma: impact of distance from the transplant center.

Lipe BC, Lansigan F, Gui J, Meehan K

Clinical advances in hematology & oncology : H&O.. 2012 January 10 (1):28-32. Epub 1900 01 01.

Granulocytic sarcoma 12 years following allogeneic marrow transplant for AML.

Lipe BC, Cogbill E, Hill J, Meehan K

Clinical advances in hematology & oncology : H&O.. 2011 December 9 (12):948-51. Epub 1900 01 01.

Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin.

Lipe B, Ornstein DL

Circulation.. 2011 October 4124 (14):e365-8. Epub 1900 01 01.

Von Willebrand disease in pregnancy.

Lipe BC, Dumas MA, Ornstein DL

Hematology/oncology clinics of North America.. 2011 April 25 (2):335-58, viii. Epub 1900 01 01.

Lipoprotein lipase links dietary fat to solid tumor cell proliferation.

Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, Swinnen JV, Timmerman LA, Chaychi L, Fricano CJ, Eisenberg BL, Coleman WB, Kinlaw WB

Molecular cancer therapeutics.. 2011 March 10 (3):427-36. Epub 01/31/2011.

An overview of angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Weber MA

The Journal of the American Osteopathic Association.. 1987 February 87 (2 Suppl):175-80. Epub 1900 01 01.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.9 stars

Likelihood of recommending this care provider to others

4.9 stars

Explanations the care provider gave you about your problem or condition

4.9 stars

Care provider's efforts to include you in decisions about your care

4.9 stars

Concern the care provider showed for your questions or worries

4.9 stars

Patient Comments

5.0 stars

Dr. Lipe listens to my concerns and responds accordingly!

Dec 26, 2024

5.0 stars

All good can't praise any higher.

Dec 13, 2024

5.0 stars

Very good always and Dr. Lipe is a wonderful care provider and we have often recommended Dr. Lipe to others.

Nov 29, 2024

5.0 stars

Dr. Bria Lipe is a very thorough and an excellent Doctor who is very involved in meeting the concerns of the patient. She was very understanding & patient listening to my needs & feelings on the proposed treatment. I would highly recommend this doctor. Dr. Lipe is brilliant, confident and the expert in the treatment of my condition.

Nov 28, 2024

5.0 stars

Dr was extremely concerned and caring

Nov 24, 2024

5.0 stars

Dr. Lipe understands my needs and it is easy to check in and discuss things this way

Nov 11, 2024

5.0 stars

Everyone listened to my concerns.

Nov 03, 2024

5.0 stars

No effort to assess pt health literacy

Oct 20, 2024

5.0 stars

Dr. Lipe treats holisticly; she made referrals (with alacrity) to other specialists I needed.

Oct 06, 2024

4.4 stars

Seemed hurried; very fast and cursory meeting

Aug 02, 2024